Last Price$233.1(0.2%)
Market Cap$34.6B
LTM FCF to Net Income
111.2%
5Y avg
89.4%
Medical - Instruments & Supplies industry
median
73.6%
Stock quality & Intrinsic value
8/10
(0.2%) overvalued
ResMed Inc. FCF to Net Income
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Jun'05 | Jun'06 | Jun'07 | Jun'08 | Jun'09 | Jun'10 | Jun'11 | Jun'12 | Jun'13 | Jun'14 | Jun'15 | Jun'16 | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FCF to Net Income | 48.4% | (4.2%) | 20.4% | 56.3% | 85.1% | 66.6% | 91.7% | 126.4% | 107.8% | 89.8% | 88.2% | 136.2% | 100.1% | 137.4% | 94.3% | 112.0% | 130.6% | 25.0% | 62.3% | 126.0% |
Overvalued or undervalued?
Check the intrinsic value for RMD
and see if it's the right time to invest.
ResMed Inc. (RMD) FCF to Net Income comparison analysis
General
LTM FCF to Net Income
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
ResMed Inc.RMD
111.2%
10.9%
13.4%
21.8%
Median Peer Set
64.8%
1.7%
23.0%
10.2%
Becton, Dickinson and CompanyBDX
170.0%
4.2%
18.3%
8.4%
Hologic, Inc.HOLX
152.6%
(0.0%)
81.1%
19.6%
Alcon Inc.ALC
129.1%
8.5%
182.9%
10.3%
AptarGroup, Inc.ATR
93.3%
2.7%
30.2%
10.5%
The Cooper Companies, Inc.COO
73.4%
8.4%
32.2%
10.1%
West Pharmaceutical Services, Inc.WST
56.1%
(1.9%)
(15.5%)
17.0%
Intuitive Surgical, Inc.ISRG
46.2%
17.2%
27.7%
27.8%
Masimo CorporationMASI
(47.7%)
0.6%
(42.5%)
4.0%
Baxter International Inc.BAX
(91.9%)
(69.5%)
(100.0%)
(6.9%)
Repligen CorporationRGEN
(633.3%)
(21.1%)
(80.9%)
5.6%
RMD key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Jun'05 | Jun'06 | Jun'07 | Jun'08 | Jun'09 | Jun'10 | Jun'11 | Jun'12 | Jun'13 | Jun'14 | Jun'15 | Jun'16 | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 425.5 25.4% | 607.0 42.7% | 716.3 18.0% | 835.4 16.6% | 920.7 10.2% | 1,092.4 18.6% | 1,243.1 13.8% | 1,368.5 10.1% | 1,514.5 10.7% | 1,555.0 2.7% | 1,678.9 8.0% | 1,838.7 9.5% | 2,066.7 12.4% | 2,340.2 13.2% | 2,606.6 11.4% | 2,957.0 13.4% | 3,196.8 8.1% | 3,578.1 11.9% | 4,223.0 18.0% | 4,685.3 10.9% |
| Cost of Goods Sold (COGS) | 150.6 | 230.1 | 331.8 | 341.6 | 366.9 | 436.9 | 501.8 | 547.8 | 573.8 | 565.2 | 667.5 | 772.2 | 865.0 | 978.0 | 1,070.0 | 1,239.2 | 1,357.7 | 1,553.8 | 1,867.3 | 2,030.0 |
% margin | 274.9 64.6% | 376.9 62.1% | 384.5 53.7% | 493.8 59.1% | 553.8 60.1% | 655.5 60.0% | 741.3 59.6% | 820.7 60.0% | 940.7 62.1% | 989.8 63.7% | 1,011.4 60.2% | 1,066.5 58.0% | 1,201.7 58.1% | 1,362.2 58.2% | 1,536.6 59.0% | 1,717.8 58.1% | 1,839.1 57.5% | 2,024.3 56.6% | 2,355.7 55.8% | 2,655.3 56.7% |
| Operating Expenses | 167.1 | 244.5 | 294.3 | 348.4 | 360.0 | 412.1 | 473.4 | 525.3 | 585.8 | 578.4 | 596.2 | 625.2 | 745.0 | 801.9 | 900.6 | 908.7 | 926.7 | 1,024.0 | 1,203.7 | 1,335.4 |
| Research & Development Expenses (R&D) | 30.0 | 37.2 | 50.1 | 60.5 | 63.1 | 75.2 | 92.0 | 109.7 | 120.1 | 118.2 | 114.9 | 118.7 | 144.5 | 155.1 | 180.7 | 201.9 | 225.3 | 253.6 | 287.6 | 307.5 |
| Selling, General & Administrative Expenses (SG&A) | 135.7 | 200.2 | 237.3 | 278.1 | 289.9 | 328.9 | 371.2 | 401.6 | 430.8 | 450.4 | 472.6 | 482.6 | 554.0 | 600.4 | 645.0 | 676.7 | 670.4 | 739.4 | 874.0 | 917.1 |
% margin | 97.4 22.9% | 131.3 21.6% | 90.2 12.6% | 143.0 17.1% | 190.3 20.7% | 240.4 22.0% | 266.9 21.5% | 294.4 21.5% | 354.8 23.4% | 405.1 26.1% | 409.2 24.4% | 429.0 23.3% | 425.8 20.6% | 541.8 23.2% | 579.3 22.2% | 809.7 27.4% | 903.7 28.3% | 1,000.3 28.0% | 1,131.9 26.8% | 1,319.9 28.2% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.7 | 27.8 | 33.9 | 38.9 | 31.2 | 26.2 | 16.9 | 17.1 | 16.4 | 2.3 | 1.0 | 0.4 | 22.3 | 47.4 | 0.0 |
| Interest Expense | 0.0 | 1.3 | 1.3 | 10.1 | 10.1 | 10.1 | 1.8 | 4.8 | 6.4 | 6.1 | 5.8 | 11.2 | 28.2 | 28.4 | 36.2 | 40.4 | 24.0 | 22.3 | 47.4 | 45.7 |
| Pre-tax Income | 96.6 | 133.4 | 98.0 | 157.9 | 201.7 | 260.6 | 303.7 | 331.9 | 385.1 | 431.1 | 435.9 | 439.6 | 418.7 | 521.3 | 518.8 | 733.1 | 883.7 | 960.5 | 1,101.7 | 1,264.8 |
% effective tax rate | 31.8 33.0% | 45.2 33.9% | 31.7 32.3% | 47.6 30.1% | 55.2 27.4% | 70.5 27.1% | 76.7 25.3% | 77.1 23.2% | 78.0 20.2% | 85.8 19.9% | 83.0 19.0% | 87.2 19.8% | 76.5 18.3% | 205.7 39.5% | 114.3 22.0% | 111.4 15.2% | 409.2 46.3% | 181.0 18.8% | 204.1 18.5% | 243.8 19.3% |
% margin | 64.8 15.2% | 88.2 14.5% | 66.3 9.3% | 110.3 13.2% | 146.4 15.9% | 190.1 17.4% | 227.0 18.3% | 254.9 18.6% | 307.1 20.3% | 345.3 22.2% | 352.9 21.0% | 352.4 19.2% | 342.3 16.6% | 315.6 13.5% | 404.6 15.5% | 621.7 21.0% | 474.5 14.8% | 779.4 21.8% | 897.6 21.3% | 1,021.0 21.8% |
| EPS | 0.47 | 0.61 | 0.43 | 0.72 | 0.97 | 1.26 | 1.49 | 1.75 | 2.15 | 2.44 | 2.51 | 2.51 | 2.42 | 2.21 | 2.83 | 4.31 | 3.27 | 5.34 | 6.12 | 6.94 |
| Diluted EPS | 0.46 | 0.58 | 0.43 | 0.70 | 0.95 | 1.23 | 1.44 | 1.71 | 2.10 | 2.39 | 2.47 | 2.49 | 2.40 | 2.19 | 2.80 | 4.27 | 3.24 | 5.30 | 6.09 | 6.92 |
% margin | 136.9 32.2% | 174.0 28.7% | 90.2 12.6% | 204.8 24.5% | 190.3 20.7% | 322.2 29.5% | 374.3 30.1% | 422.6 30.9% | 469.8 31.0% | 484.9 31.2% | 482.3 28.7% | 522.7 28.4% | 568.9 27.5% | 680.2 29.1% | 705.8 27.1% | 990.4 33.5% | 1,099.2 34.4% | 1,176.6 32.9% | 1,358.8 32.2% | 1,533.5 32.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is ResMed Inc.'s FCF to Net Income?
As of today, Microsoft Corp's last 12-month FCF to Net Income is 111.2%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual FCF to Net Income for ResMed Inc. have been 80.2% over the past three years, and 93.9% over the past five years.
2) Is ResMed Inc.'s FCF to Net Income Good?
As of today, ResMed Inc.'s FCF to Net Income is 111.2%, which is higher than industry median of 73.6%. It indicates that ResMed Inc.'s FCF to Net Income is Good.